Details for Patent: 9,649,311
✉ Email this page to a colleague
Which drugs does patent 9,649,311 protect, and when does it expire?
Patent 9,649,311 protects ISENTRESS HD and is included in one NDA.
Protection for ISENTRESS HD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-three patent family members in twenty-six countries.
Summary for Patent: 9,649,311
Title: | Solid pharmaceutical compositions containing an integrase inhibitor |
Abstract: | Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described. |
Inventor(s): | Mahjour; Majid (Schwenksville, PA), Li; Feng (Dresher, PA), Ma; Decheng (Souderton, PA), Sotthivirat; Sutthilug (Lansdale, PA) |
Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
Application Number: | 13/503,939 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Process; Dosage form; |
Drugs Protected by US Patent 9,649,311
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | ISENTRESS HD | raltegravir potassium | TABLET;ORAL | 022145-002 | May 26, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,649,311
PCT Information | |||
PCT Filed | October 21, 2010 | PCT Application Number: | PCT/US2010/053507 |
PCT Publication Date: | May 05, 2011 | PCT Publication Number: | WO2011/053504 |
International Family Members for US Patent 9,649,311
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2010313571 | ⤷ Try a Trial | |||
Brazil | 112012009857 | ⤷ Try a Trial | |||
Canada | 2777937 | ⤷ Try a Trial | |||
China | 102655752 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |